Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin

C Larsen, Larsen C, Niebuhr Jørgensen M, M Niebuhr Jørgensen, Tommerup B, B Tommerup, Mygind N, N Mygind, E E Dagrosa, Dagrosa EE, H G Grigoleit, Grigoleit HG, V Malerczyk, Malerczyk V
European journal of clinical pharmacology · 1987 · doi:10.1007/BF00544560 · PMID:3121354
other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-14 ⓘ

Experimental rhinitis induced by histamine did not alter the luteinizing hormone response to intranasal buserelin in male volunteers compared to saline controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-14 · read from full text ⓘ

This study investigated whether experimental rhinitis affects absorption of intranasal buserelin by measuring the subsequent serum luteinizing hormone (LH) response. Twenty-four healthy men received a single 200 µg dose of buserelin via nasal pump-spray after either histamine-induced rhinitis or a saline spray placebo, and LH rises were used to assess gonadotropin response; one occasion reflected a likely incorrect pump operation. Except for that case, serum LH increased after buserelin, and there was no difference in LH response between histamine rhinitis and saline controls. The authors concluded intranasal buserelin is reliable and that dose/route modification during naturally occurring nasal inflammation (including allergic rhinitis or common cold) is unnecessary for chronic intranasal buserelin use, and they explicitly mention endometriosis among target conditions for chronic treatment, even though the experiment itself was conducted in healthy males without endometriosis. This paper is centrally about endometriosis — it discusses chronic intranasal buserelin for endometriosis as an application of the findings about nasal inflammation not altering gonadotropin response.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The influence of experimental rhinitis on the absorption of buserelin, measured as the serum luteinizing hormone (LH) response, has been investigated. A single dose of 200 micrograms buserelin was given to 24 healthy male volunteers after induction of experimental rhinitis with histamine and after use of a saline spray (placebo control). Except on one occasion, when the pump-spray apparently was incorrectly operated, serum LH concentration rose after buserelin. There was no difference in the LH response between histamine-induced rhinitis and saline controls. It was concluded that intranasal application of buserelin represents a reliable mode of application and that modification of the administration route or a change in the dosage schedule during naturally-occurring nasal inflammations, such as the common cold and allergic rhinitis, is unnecessary in patients undergoing chronic treatment with intranasal buserelin, e.g. for prostatic cancer, endometriosis, precocious puberty, and contraception.
Full text 5,441 characters · extracted from oa-doi-fallback · click to expand
Summary The influence of experimental rhinitis on the absorption of buserelin, measured as the serum luteinizing hormone (LH) response, has been investigated. A single dose of 200 µg buserelin was given to 24 healthy male volunteers after induction of experimental rhinitis with histamine and after use of a saline spray (placebo control). Except on one occasion, when the pump-spray apparently was incorrectly operated, serum LH concentration rose after buserelin. There was no difference in the LH response between histamine-induced rhinitis and saline controls. It was concluded that intranasal application of buserelin represents a reliable mode of application and that modification of the administration route or a change in the dosage schedule during naturally-occurring nasal inflammations, such as the common cold and allergic rhinitis, is unnecessary in patients undergoing chronic treatment with intranasal buserelin, e.g. for prostatic cancer, endometriosis, precocious puberty, and contraception. Similar content being viewed by others References Lemay A, Quesnel G (1982) Potential new treatment of endometriosis: Reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 38: 376–379 Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41: 863–871 Shaw RW, Fraser HM, Boyle H (1983) Intranasal treatment with luteinizing hormone releasing hormone agonist in women with endometriosis. Br Med J 287: 1667–1669 Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM, Schally AV (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonist. Med Sci 79: 1658–1662 Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Thabet M, Roy R, Fazekas ATA (1983) Preliminary results on the clinical efficacy and safety of androgen inhibition by a LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 4: 601–624 Wenderoth UK, Jacobi GH (1985) Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular GN-RH analogue treatment. In: Schroeder FH, Richards B (eds) OERTC Genito-urinary Group Monograph 2, part A: Therapeutic principles in metastatic prostatic cancer. Alan R Liss, New York pp 297–305 Klijn JG, de Jong FH (1982) Treatment with a luteinising-hormone releasing-hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1: 1213–1216 Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein AM (1985) LH-RH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873 Luder AS, Holland FJ, Costigan DC, Jenner MR, Wielgosz G, Fazekas ATA (1984) Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 58: 966–972 Nillius SJ, Bergquist C, Wide L (1978) Inhibition of ovulation in women by chronic treatment with a stimulatory LHR analogue — a new approach to birth control? Contraception 17: 537–545 Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, von der Ohe M, Nevinny-Stickel J (1981) Influence of the LHRH analogue buserelin in cyclic ovarian function and on endometrium. A new approach to fertility control? Contraception 23: 187–195 Sandow J, Clayton RN, Kuhl H (1981) Pharmacology of LHRH and its analogues. In: Crosignani PG, Rubin BL (eds) Endocrinology of human infertility: New aspects. Academic Press, London, pp 221–246 Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R (1982) Sustained suppression of testosterone production by the luteinizing hormone releasing hormone agonist buserelin in patients with advanced prostate carcinoma: A new therapeutic approach. Lancet 1: 1097–1099 Petri W, Seidel R, Sandow J (1984) A pharmaceutical approach to long-term therapy with peptides. In: Labrie F, Belanger A, Dupont A (eds) LHRH and its analogues. Busic and clinical aspects. The Netherlands: Elsevier B. V., Amsterdam, pp 63–76 Lawrence JR, McEwen J, Pidgen AW, Robinson JD (1981) Dose response characteristics of D-ser (TBU)6-Des gly10-LHRH-ethylamide (HOE 766 — Buserelin) following intranasal administration to five healthy male volunteers. Br J Clin Pharmacol 13: 297P-298P Secher C, Kirkegaard J, Borum P, Maansson A, Osterhammel P, Mygind N (1982) Significance of H1- and H2-receptors in the human nose: Rationale for use of combined preparations. J Allergy Clin Immunol 70: 211–218 Broms P, Ivarsson A, Jonson B (1982) Rhinomanometry I — Simple equipment. Acta Otolaryngol (Stockh) 93: 455–460 Broms P, Jonson B, Lamm CJ (1982) Rhinomanometry II — A system for numerical description of nasal airway resistance. Acta Otolaryngol (Stockh) 94: 157–168 Author information Authors and Affiliations Rights and permissions About this article Cite this article Larsen, C., Jørgensen, M.N., Tommerup, B. et al. Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin. Eur J Clin Pharmacol 33, 155–159 (1987). https://doi.org/10.1007/BF00544560 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF00544560

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Buserelin Luteinizing Hormone Rhinitis Absorption Administration, Intranasal Adult Airway Resistance Airway Resistance Biological Availability Buserelin Buserelin Buserelin Female Histamine Histamine Humans Luteinizing Hormone Male Random Allocation Rhinitis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
pubmed
last seen: 2026-05-13T22:09:35.489789+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine